U.S. Markets closed

HC Wainwright Says Viaskin Benefit Affirmed In Toddlers...What's Next?

·1 min read
  • HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ: DBVTtrial update was that 250ug treatment achieved the primary endpoint of difference between the percentage of treatment responders in the active compared to the placebo arm after 12 months.

  • It reiterates a Buy rating and a $10 price target.

  • Moreover, the analysts highlight that the lower bound of the 95% confidence interval was 22.4%, comfortably exceeding the prespecified 15% threshold.

  • The analysts emphasize that the Phase 3 EPITOPE trial was much more conservative in its safety assessment compared to the context of oral immunotherapy Palforzia.

  • They note that 1.6% of patients in the Viaskin arm, compared to 0% placebo, experienced an anaphylactic reaction related to or possibly related to treatment while not necessarily requiring epinephrine.

  • HC Wainwright specifically compares it to Aimmune Therapeutics Inc's Palforzia.

  • Along with black box anaphylactic reaction risk, the analysts note Palforzia demonstrated 9.4% of patients with anaphylaxis in combined studies during dose escalation and up-dosing compared to 3.8% for placebo, highlighting Viaskin's EPIT differentiation from a safety standpoint, while delivering on efficacy with a minimal peanut allergen.

  • Price Action: DBVT shares are up 14.54% at $1.75 during the market session on the last check Wednesday.

Latest Ratings for DBVT






Dec 2021

JMP Securities


Market Outperform

Dec 2021

HC Wainwright & Co.



Aug 2020

Morgan Stanley



View More Analyst Ratings for DBVT

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.